Author's response to reviews

Title: Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer

Authors:

Sheng Zhang (568841700@qq.com)
Qing Wang (13795218205@qq.com)
Yun Ling (18017317442@163.com)
Xichun Hu (wozhangsheng@hotmail.com)

Version: 2 Date: 30 October 2014

Author's response to reviews: see over
Dear Editor,

We believe our study here adds new insight into the understanding of the current treatment for low risk febrile neutropenic cancer patients. 

category: clinical research 

journal: BMC cancer

The manuscript is sent to your journal and is not considered for publication elsewhere. All authors have read and approved the manuscript. all authors have agreed to the submission to the journal

Thanks very much

Dr Xichun Hu

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, shanghai, China. Tel: 86-21-67822026 email: wozhangsheng@gmail.com

novelty: The high sensitivity of the blood culture isolates to fluoroquinolone from low risk febrile neutropenic patients is the basis for quinolone-based treatment which was recommended by NCCN
A total of 38 low risk patients with positive blood cultures (this is the biggest data set regarding this topic.) were included in this analysis. A very high drug resistance was observed: 13 out of 28 *Escherichia coli* isolates (46%) or 14 out of all 38 positive cultures (37%).

The results warrant further validations.